产品封面图
文献支持

pTYB1

收藏
  • ￥1080
  • LSM Bio
  • 进口
  • PVT0820
  • 2025年07月01日
    avatar
    武汉维克赛思科技有限公司
    8 年钻石会员

  • 企业认证

    点击 QQ 联系

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件：

      负20摄氏度

    • 保质期：

      3个月

    • 英文名：

      pTYB1

    • 库存：

      100

    • 供应商：

      LSMBIO

    • 规格：

      2ug

    pTYB1

    Search name

    pTYB1,Plasmid pTYB1,pTYB1 vector

    pTYB1 Plasmid informaiton

    Promoter: T7
    Replicon: M13 ori
    Plasmid classification: Escherichia coli vector; protein expression plasmid
    Plasmid size: 7477bp
    Plasmid label: Intein
    Prokaryotic resistance: ampicillin Amp
    Cloned strain: DH5 alpha
    Culture conditions: 37 centigrade, aerobic, LB
    Expression host: Escherichia coli
    Culture conditions: 37 centigrade, aerobic, LB
    5'sequencing primers: T7:TAATACGACTCACTATAGGG
    3'sequencing primers: Based on sequence design
    Remarks: expression plasmids

    pTYB1 Plasmid Description
    The pTYB1 is an E. coli vector created for fusion protein expression and purification. A target gene can be inserted into the the ORF by use of the MCS upstream of the Sce VMA intein. The NdeI site in the MCS has the initiator sequence ATG that enables translation of the ORF. The chitin-binding domain(CBD) downstream of the intein results in a target protein-intein with C-terminal chitin beads that facilitate protein purification. Release of the protein is induced by the thiol cleavage activity of the intein.

    pTYB1 Plasmid Sequence
    LOCUS       pTYB1 7477 bp  DNA SYN
    DEFINITION  pTYB1
    ACCESSION  
    KEYWORDS   
    SOURCE     
      ORGANISM  other sequences; artificial sequences; vectors.
    FEATURES             Location/Qualifiers
         source          1..7477
                         /organism="pTYB1"
                         /mol_type="other DNA"
         promoter        70..98
                         /label="AmpR_promoter"
         gene            140..1000
                         /label="Ampicillin"
                         /gene="Ampicillin"
         CDS             140..1000
                         /label="ORF frame 2"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERSPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
         rep_origin      complement(1232..1538)
                         /label="f1_origin"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERSPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
         rep_origin      1650..2269
                         /label="pBR322_origin"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERSPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
         misc_feature    2607..2629
                         /label="pGEX_3_primer"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERSPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
         misc_feature    complement(2623..2814)
                         /label="ROP"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERSPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
         CDS             2953..3588
                         /label="ORF frame 1"
                         /translation="MDAAGPEKNHSGSMPAERQQDVAQRVGRHAGDNGLLLAETFGGG
                         TSDEGLSEGVQDSEYRKRQADHRRAPAKAVLAENDPERCRHLSYELHDKEDSHKCGDD
                         SHAPRPPEGADWVEGSQGHRSRSRCLMSELTYINCVALTARFPVGKPVVPAALMNRPT
                         RGERRFAYWAPGWFFFSPVRRATADCPSPPGPERVAASGPRWFAPAGENPV*"
         gene            complement(3010..3309)
                         /label="tet (611 - 312)"
                         /gene="tet (611 - 312)"
                         /translation="MDAAGPEKNHSGSMPAERQQDVAQRVGRHAGDNGLLLAETFGGG
                         TSDEGLSEGVQDSEYRKRQADHRRAPAKAVLAENDPERCRHLSYELHDKEDSHKCGDD
                         SHAPRPPEGADWVEGSQGHRSRSRCLMSELTYINCVALTARFPVGKPVVPAALMNRPT
                         RGERRFAYWAPGWFFFSPVRRATADCPSPPGPERVAASGPRWFAPAGENPV*"
         misc_feature    complement(3371..4462)
                         /label="lacI"
                         /translation="MDAAGPEKNHSGSMPAERQQDVAQRVGRHAGDNGLLLAETFGGG
                         TSDEGLSEGVQDSEYRKRQADHRRAPAKAVLAENDPERCRHLSYELHDKEDSHKCGDD
                         SHAPRPPEGADWVEGSQGHRSRSRCLMSELTYINCVALTARFPVGKPVVPAALMNRPT
                         RGERRFAYWAPGWFFFSPVRRATADCPSPPGPERVAASGPRWFAPAGENPV*"
         CDS             complement(3371..4330)
                         /label="ORF frame 1"
                         /translation="MAELNYIPNRVAQQLAGKQSLLIGVATSSLALHAPSQIVAAIKS
                         RADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNV
                         PALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGW
                         HKYLTRNQIQPIAEREGDWSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITE
                         SGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQ
                         LLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ*"
         CDS             complement(4654..5415)
                         /label="ORF frame 2"
                         /translation="MPGELIPGSLWRASCPPPSGPLLRNVQIRSRRICPTQESVHRQT
                         TDKTKGPVFRLSLSFYLMPGELIPGSLWRASCPPPSGPLLRNVQIRSRRICPTQESVH
                         RQTTDKTKGPVFRLSLSFYLMPGELIPGSLWRASCPPPSGPLLRNVQIRSRRICPTQE
                         SVHRQTTDKTKGPVFRLSLSFYLMPGELIPGSLWRASCPPPSGPLLRNVQIRSRRICP
                         TQESVHRQTTDKTKGPVFRLSLSFYLMPGELGINS*"
         terminator      4687..4730

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation Author：YangZhang1YiXu1WenyunLu23Jonathan M.Ghergurovich24LiliGuo56Ian A.Blair5Joshua D.Rabinowitz23XiaoluYang17 Received 22 January 2020, Revised 4 August 2020, Accepted 30 September 2020, Available online 6 November 2020. Published: November 6, 2020 Cell Metabolism Available online 6 November 2020 In Press doi: doi.org/10.1016/j.cmet.2020.10.002
    相关实验

    • NEB原核表达系统

      -CN蛋白纯化 系统,可利用还原剂DTT使标签自动裂解,无需外加蛋白酶切割,可以在4度条件下进行,小分子的还原剂也很容易去除;IMPACT-CN蛋白纯化系统包含的表达载体(pTYB载体)有两种,内含肽分别与目的蛋白的C末端(pTYB1和 pTYB2)或N末端(pTYB11和pTYB12)融合.这种在融合蛋白构建方面的机动性极大优化了目的蛋白成功表达和纯化的能力.pTYB2和 pTYB12载体的多克隆位点区设计了相同或者可兼容的酶切位点,使得目的蛋白可选择任一种融合构建载体.而pTYB1及pTYB

    • 去Tag不留痕――NEB原核表达系列

      载体（pTYB载体）有两种，内含肽分别与目的蛋白的C末端（pTYB1和pTYB2）或N末端（pTYB11和pTYB12）融合。这种在融合蛋白构建方面的机动性极大优化了目的蛋白成功表达和纯化的能力。pTYB2和pTYB12载体的多克隆位点区设计了相同或者可兼容的酶切位点，使得目的蛋白可选择任一种融合构建载体。而pTYB1及pTYB11载体可让目的基因与内含肽的裂解位点直接相连，在4℃利用 DTT 诱导内含肽的肽键裂解活性，使得最后纯化得到的天然蛋白不带有源自于载体的额外的蛋白残基，同时低温也最大程度地保

    • 质粒图谱大全·如何阅读质粒图谱

      X-3 pGEX-6P-1 pGEX-6P-2 pGEX-6P-3 五.PTYBsystem PTYB1 PTYB2 PTYB11 PTYB12 六.真核表达载体 pCDNA3.1(-) pCDNA3.1( ) pPICZalphaA pGAPZαA

    查看更多相关实验 >
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    pTYB1
    ¥800
    上海钰博生物科技有限公司
    2025年07月12日询价
    pTYB2
    ￥1080
    武汉维克赛思科技有限公司
    2025年08月31日询价
    pTYB1
    ¥1
    上海联迈生物工程有限公司
    2025年07月14日询价
    pTYB1
    ￥1200
    上海晶风生物科技有限公司
    2025年11月19日询价
    pTYB1载体
    ￥1000
    上海盖宁生物科技有限公司
    2025年12月23日询价
    文献支持
    pTYB1
    ￥1080